HeartBeam and AccurKardia Join Forces to Advance Remote Cardiac Monitoring 

In a significant move that could make a difference in remote cardiac care, HeartBeam, Inc., a pioneer in medical technology, has announced a strategic collaboration with AccurKardia, an innovator in ECG-based diagnostics. This partnership unites two leaders in ambulatory electrocardiogram (ECG) recording and analysis to create a powerful, patient-centered cardiac monitoring solution.

Elevating Accessibility and Speed in Cardiac Diagnostics

The initial phase of the collaboration focuses on integrating AccurKardia’s FDA-cleared AccurECG™ software with HeartBeam’s devices. This strategic initiative aims to make advanced cardiac monitoring more accessible to individuals outside of traditional healthcare settings.

“This collaboration is a major step forward in delivering a more accessible and scalable solution for remote cardiac monitoring,” said Robert Eno, Chief Executive Officer of HeartBeam, in a statement. “AccurKardia shares our mission of improving cardiac outcomes through technological innovation, and together we can accelerate the delivery of unprecedented cardiac insights to individuals and physicians outside of a medical facility.”

HeartBeam’s revolutionary credit card-sized, cable-free 3D ECG device captures the heart’s electrical signals in three non-coplanar directions, synthesizing these into a full 12-lead ECG using a personalized transformation matrix. The company plans to initiate commercialization of this technology following FDA clearance for the 12-lead ECG synthesis software.

Adding AccurKardia’s device-agnostic automated ECG interpretation platform will enable HeartBeam to offer immediate, automated rhythm assessments. This rapid diagnostic capability promises to facilitate faster clinical decision-making and improve patient outcomes through expedited access to care.

Also Read: AccurKardia Earns FDA Breakthrough Device Designation for AK+ Guard™

Transforming Patient Empowerment and Healthcare Delivery

The integration of HeartBeam’s compact device with AccurKardia’s advanced analytics is designed to empower patients by placing clinical-grade ECG insights directly into their pockets. This innovation addresses a critical gap in the U.S. healthcare system: the increasing lack of access to cardiology specialists.

“We believe combining AccurKardia’s device‑agnostic, FDA‑cleared automated ECG analytics with HeartBeam’s novel credit card‑sized device will be a true game‑changer,” said Juan C. Jimenez, Co-Founder and Chief Executive Officer of AccurKardia, an MTI alum. “By uniting our strengths, we’re creating a best‑in‑class platform that transforms how cardiac arrhythmia conditions are monitored and detected.”

Beyond improving diagnostic speed and accuracy, the collaboration is also expected to accelerate HeartBeam’s product development, reducing both costs and timelines, thereby enhancing the scalability of remote cardiac monitoring solutions.

Note: The combined HeartBeam–AccurKardia solution is under development and has not yet been cleared by the U.S. Food and Drug Administration.

MedTech World Bay Area

MedTech World Bay Area, happening on June 27, 2025, offers sponsors and investors a focused opportunity to engage directly with 100 fundraising startups and leading voices in medical technology. Held in collaboration with MedTech Innovator, this exclusive event is designed to spark meaningful conversations, identify high-potential ventures, and build strategic relationships in a single day. If you’re looking to align your brand with innovation or connect with the next generation of MedTech companies, this is the event to attend. To explore sponsorship options or secure your place, contact us at [email protected].